Agios Pharmaceuticals (AGIO) Common Equity (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Common Equity data on file, last reported at $1.0 billion in Q2 2026.

• Quarterly Common Equity fell 25.08% year-over-year to $1.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.0 billion (down 25.08% YoY) and the FY2025 annual result came in at $1.2 billion, down 22.57% from the prior year.
• Common Equity eased to $1.0 billion in Q2 2026, from $1.1 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.6 billion in Q3 2024 to a low of $660.5 million in Q2 2024.
• A 5-year average of $1.1 billion and a median of $1.1 billion in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity slumped 47.43% — and 2025, when it jumped 107.35%.
• Tracing AGIO's Common Equity over 5 years: stood at $1.1 billion in 2022, then decreased by 26.33% to $811.0 million in 2023, then jumped by 90.0% to $1.5 billion in 2024, then declined by 22.57% to $1.2 billion in 2025, then fell by 14.0% to $1.0 billion in 2026.
• The last three Common Equity figures came in at $1.0 billion (Q2 2026), $1.1 billion (Q1 2026), and $1.2 billion (Q4 2025), per Business Quant data.